Uncategorized

Calliditas Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB, announced that the global open-label extension study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration and estimated glomerular filtration rate at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd

Calliditas Announces Positive NefIgArd Open Label Extension Results Read More »

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate ‘BH3120’ in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab) Read More »

Scroll to Top